600062.SH
China Resources Double-Crane Pharmaceutical Co., Ltd.
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 15.83
+1.02%Price chart
Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18
Key dataSep 18, 2026
OpenCNY 15.79
From 52W high−19.64%
Volume4.51M
Market capCNY 16.44B
P/E (TTM)10.0x
P/S (TTM)1.5x
Div yield3.02%
Key dataSep 18, 2026
Open
CNY 15.79
From 52W high
−19.64%
Volume
4.51M
Market cap
CNY 16.44B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
5.9x
P/E (TTM)
10.0x
RSI (14)
44.0
MomentumView details →
1D Return
+1.02%
YTD Return
−13.23%
Similar companies
Latest newsMore news →
China Resources Double-Crane's wholly owned subsidiary China Resources Saike received drug registration certificates from the National Medical Products Administration for Ezetimibe and Atorvastatin Calcium Tablets (I) and (II), approved for market on September 8, 2026.6d agoChina Resources Double-Crane announced that its Compound Glucose/Electrolyte Craniotomy Irrigation Solution received a drug registration certificate from the National Medical Products Administration, and the product is deemed to have passed consistency evaluation, but it can only be marketed after the production line passes GMP compliance inspection.12d agoChina Resources Double Crane announced that its lomustine capsules received a drug registration certificate and were approved for market launch by the National Medical Products Administration on August 25, 2026, with a 6-year data protection period.19d ago